Profile of clinical efficacy and safety of topical tacalcitol

Acta Biomedica de l'Ateneo Parmense

Volumn 76, Issue 1, 2005, Pages

  Leone, Giovanni ^a   Pacifico, Alessia ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Psoriasis; Topical treatment; Vitamin D3 analogues; Vitiligo

Indexed keywords

ALPHOSYLE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; DITHRANOL; ETRETINATE; HYDROCORTISONE BUTYRATE; KERATOLYTIC AGENT; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; PSORALEN; SALICYLIC ACID; TACALCITOL; TAR; TAZAROTENE; UNCLASSIFIED DRUG; UREA;

BURNING SENSATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSKERATOSIS; EPIDERMODYSPLASIA VERRUCIFORMIS; ERYTHEMA; HUMAN; HYPERPIGMENTATION; IMMUNOCOMPETENT CELL; KERATINOCYTE; OINTMENT; PHOTOTHERAPY; PRURITUS; PSORIASIS; PUVA; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN IRRITATION; SOLAR RADIATION; TRANSIENT ACANTHOLYTIC DERMATOSIS; ULTRAVIOLET B RADIATION; VITILIGO; WART VIRUS;

ADULT; AGED; CLINICAL TRIALS; DERMATOLOGIC AGENTS; DIHYDROXYCHOLECALCIFEROLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KERATINOCYTES; MALE; MULTICENTER STUDIES; OINTMENTS; PHOTOTHERAPY; PSORIASIS; PUVA THERAPY; SKIN DISEASES; TIME FACTORS; VITILIGO;

EID: 22244478968     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Eyre RW, Krueger GG. The Koebner response in psoriasis. In: Roenigk HH jr, Maibach HI editors. Psoriasis. 2nd edition. New York: Marcel Dekker 1991; 135-47.
2. Faber EM, Rein G, Lanigan SW. Stress and psoriasis. Int J Dermatol 1991; 30: 8-12.
3. Baker H. The influence of chloroquine and related drugs on psoriasis and keratoderma blenorrhagicum. Br J Dermatol 1996; 78: 161-6.
4. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002; 146: 351-64.
5. Kragballe K. The use of vitamine D analogues in dermatology. Curr Opin Dermatol 1995; 16: 198-203.
6. Van de Kerkhof PC. An update on vitamin D3 analogues in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 1998; 11: 2-10.
7. Van de Kerkhof PC. New developments in the treatment of psoriasis. Skin Appl Skin Physiol 2001; 14: 129-35.
8. Takahashi H, Ibe M, Kinouchi M, Ishida-Yamamoto A, lizuka H. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003; 31: 21-8.
9. Kira M, Kobayashi T, Yoshikawa K. Vitamin D and the s&n. J Dermatol 2003; 30: 429-37.
10. Nishimura M, Hori Y, Nishiama S, Nakamizo Y. Topical 1a, 24 (R) -dihydroxyvitamin D3, for the treatment of psoriasis. Review of the literature. Eur J Dermatol 1993; 3: 255-61.
11. Matsunaga T, Yamamoto M, Mimura H, et al. 1,24 (R) -dyhidroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity. J Dermatol 1990; 17: 135-42.
12. Peters DC, Balfour JA. Tacalcitol. Drugs 1997; 54: 265-71.
13. Gollnick H, Menke T. Current experience with tacalcitol ointment in the treatment of psoriasis. Curr Med Res Opin 1998; 14: 213-8.
14. Van de Kerkhof PCM, Werfel T, Haustein UF, et al. Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 1996; 135: 758-65.
15. Van de Kerkhof PCM, Van der Vleuten C, Gerritsen M, et al. Long term efficacy and safety of once daily treatment of chronic plaque psoriasis with tacalcitol ointment. Eur J Dermatol 1997; 7: 421-5.
16. Scarpa C. Tacalcitol ointment is an efficacious and well tolerated treatment for psoriasis. J Eur Acad Dermatol Venereol 1996; 6: 142-6.
17. Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double blind trial. Er J Dermatol 1997; 137: 581-6.
18. Kokelj F, Plozzer C, Guadagnini A. Topical tacalcitol reduces the total UVB dosage in the treatment of psoriasis vulgaris. J Dermatol Treat 1996; 7: 265-6.
19. Sato H, Ogino Y, Takagi H, et al. Pharmacological profiles of high-concentration (20 microg/g) tacalcitol ointment: effects on cutaneous inflammation, epidermal proliferation, and differentiation in mice. J Dermatol 2003; 30: 510-24.
20. Glaser R, Rowert J, Mrowietz U. Hyperpigmentation due to topical calcipotriol and photochemotherapy in two psoriatic patients. Br J Dermatol 1998; 197: 167-70.
21. Katayama I, Ashida M, Maeda A, Eishi K, Murota H, Bae SJ. Open trial of topical tacalcitol and solar irradiation for vitiligo vulgaris:upregulation of c-Kit mRNA by cultured melanocytes. Eur J Dermatol 2003; 13: 372-6.
22. Leone G, Iacovelli P, Picardo M. Tacalcitol and narrow band UVB phototherapy in patients with vitiligo: preliminary report. Pigment Cell Research 2001; 14 (5).
23. Hayashi J, Matsui C, Mitsuishi T, Kawashima M, Morohashi M. Treatment of localized epidermodysplasia verruciformis with tacalcitol ointment. Int J Dermatol 2002; 41: 817-20.
24. Hayashi H. Treatment of Grover's disease with tacalcitol. Clin Exp Dermatol 2002; 27: 160-5.
25. Henseler T. The genetics of psoriasis. J Am Acad Dermatol 1997; 37: S1-11.
26. Weinstein GD, Krueger GG. An overview of psoriasis. In: Weinstein GD, Gottlieb AB editor. Therapy of moderate to severe psoriasis. Portland, Oregon: National Psoriasis Foundation 1993; 2-22.
27. Harrison PV. Topical tacalcitol treatment for psoriasis. Hosp Med 2000; 61: 402-5.
28. Kobayashi H, Fukaya T, Ogiso Y, et al. Vitamin D3 inhibits the mRNA expressions of fos and myc oncogenes in organ cultured skin. J Invest Dermatol 1991; 96: 616.
29. Gerritsen MJP, Boezeman JBM, van Vlijmen-Willems IMJJ, et al. The effect of tacalcitol on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double blind study. Br J Dermatol 1994; 131: 57-63.
30. Fukuoka M, Ogino Y, Sato H, et al. Production of chemokines RANTES and IL-8, and its modulation by tacalcitol in cultured human fibroblast. J Eur Dermatol Venereol 1996; 7 (suppl 2): S182.
31. Baadsgaard O, Traulsen J, Roed-Petersen J, et al. Optimal concentration of tacalcitol in once-daily treatment of psoriasis. J Dermatol Treat 1995; 6: 145-50.